1. Home
  2. FMC vs AAPG Comparison

FMC vs AAPG Comparison

Compare FMC & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FMC Corporation

FMC

FMC Corporation

HOLD

Current Price

$11.85

Market Cap

2.0B

Sector

Industrials

ML Signal

HOLD

AAPG

Ascentage Pharma Group International American Depository Shares

HOLD

Current Price

$17.60

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMC
AAPG
Founded
1910
2009
Country
United States
China
Employees
N/A
767
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
FMC
AAPG
Price
$11.85
$17.60
Analyst Decision
Hold
Strong Buy
Analyst Count
13
5
Target Price
$18.50
$48.40
AVG Volume (30 Days)
2.7M
8.8K
Earning Date
04-29-2026
05-20-2026
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,727,800,000.00
N/A
Revenue This Year
$7.89
$290.34
Revenue Next Year
$4.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.72
$16.92
52 Week High
$44.68
$48.45

Technical Indicators

Market Signals
Indicator
FMC
AAPG
Relative Strength Index (RSI) 41.70 37.96
Support Level N/A N/A
Resistance Level $14.31 $27.98
Average True Range (ATR) 0.65 0.74
MACD -0.06 -0.06
Stochastic Oscillator 36.44 16.43

Price Performance

Historical Comparison
FMC
AAPG

About FMC FMC Corporation

FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.

About AAPG Ascentage Pharma Group International American Depository Shares

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

Share on Social Networks: